ProStrakan acquires US commercial rights to Fareston for treatment of metastatic brea
ProStrakan Group plc announces today that it has acquired exclusive US commercial rights to Fareston (toremifene citrate) for the treatment of metastatic breast cancer in postmenopausal women.